# US 2026/0076904 A1 · Nano-particles of menaquinone-9 and methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076904 A1
- Document ID: US20260076904A1
- Status: Published application
- Kind: A1
- Application number: 19/272,744
- Filed: 2025-07-17
- Published: 2026-03-19
- Earliest claimed: 2023-02-21
- Assignees: Epizon, Inc.
- Applicants: Epizon, Inc.
- Inventors: Sam L. Nguyen; John M. Rudey
- Web page: https://patentgrep.com/patent/US20260076904A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A composition, comprising:
nanoparticles of MK-9 (menaquinone-9) or MKH2-9 (menaquinol-9), or a mixture thereof;
water; and
polyoxyl castor oil,
wherein the nanoparticles have an average particle size of less than or equal to 35 nm.

### Claim 31 (depends on 30)

The composition of claim 30, where the nanoparticles are prepared using a homogenizer selected from the group consisting of a rotor stator homogenizer, a bead mill homogenizer or a mortar and pestle homogenizer.

### Claim 32 (depends on 30)

The composition of claim 30, further comprising at least one emulsifier selected from the group consisting of Poloxamer 188, Polysorbate 80, Polysorbate 20, Vit E-TPGS, TPGS-1000, TPGS-750-M, PEG-40 Hydrogenated castor oil, PEG-35 Castor oil, PEG-8-glyceryl caprylate/caprate, PEG-32-glyceryl laurate, PEG-32-glyceryl palmitostearate, Polysorbate 85, polyglyceryl-6-dioleate, sorbitan monooleate, glyceryl caprylate/caprate, mixture of mono-, di- and triglycerides of oleic and linoleic acid, glyceryl monooleate, glyceryl monolinoleate, PEG-6-glyceryl oleate, PEG-6-glyceryl linoleate, oleic acid, linoleic acid, propylene glycol monocaprylate, propylene glycol monolaurate, polyglyceryl-3 dioleate, polyglyceryl-3 diisostearate and lecithin.

### Claim 33 (depends on 30)

The composition of claim 30, wherein the emulsifier is selected from Polysorbate 80, Vit E-TPGS, PEG-40 Hydrogenated castor oil and PEG-35 Castor oil.

### Claim 34 (depends on 30)

The composition of claim 30, further comprising at least one bioavailability enhancer selected from the group consisting of medium chain fatty acids, omega-3 fatty acids, capric acid, caprylic acid, alkylglycosides, chitosan, trimethylated chitosan, ethylene glycol tetraacetic acid, ethylene diamine tetraacetic acid, salicylic acid, genistein (5,7-Dihydroxy-3-(4-hydroxyphenyl) chromen-4-one)), and their pharmaceutically acceptable salts.

### Claim 35 (depends on 30)

The composition of claim 30, wherein the composition is a nanosuspension in water.

### Claim 36 (depends on 30)

The composition of claim 30, further comprising a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K.

### Claim 37 (depends on 30)

A method for the treatment of a disease in a mammal selected from the group consisting of neurodegenerative diseases, retinopathy, rheumatoid polyarthritis, atherosclerosis, amyotrophic lateral sclerosis, cerebral ischemia, cataracts, systemic infections, pathologies associated with cutaneous aging and with senescence in tissues, pathologies associated with mitochondrial dysfunction, cachexia associated with under nutrition, wherein the treatment is associated with the increase in the longevity of mammals, the method comprises the administration of a therapeutically effective amount of the composition of claim 30.

### Claim 38 (depends on 30)

A method for treating a mammal with a disease selected from the group consisting of vitamin K deficiency, osteoporosis, a proliferative disease, and a cardiovascular disease, comprising administering to the mammal a therapeutically effective amount of the composition of claim 30.

### Claim 39 (depends on 30)

A method for the treatment or prevention of osteoporosis and/or osteopenia, the method comprising administering to a patient in need of treatment, a therapeutically effective amount of a composition of claim 30.

### Claim 40 (depends on 30)

A method of treating, preventing, slowing the progression of, arresting, and/or reversing calciphylaxis in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of claim 30, and a pharmaceutically acceptable excipient, to prevent, slow the progression of, arrest, or reverse calciphylaxis.

### Claim 41 (depends on 40)

The method of claim 40, wherein the mammal has distal calciphylaxis and/or central calciphylaxis.

### Claim 42 (depends on 40)

The method of claim 40, wherein the mammal has diabetes, chronic kidney disease or end stage renal disease.

### Claim 43 (depends on 40)

The method of claim 40, wherein the mammal has chronic obstructive pulmonary disease (COPD).

### Claim 44 (depends on 40)

The method of claim 40, wherein the mammal has a calciphylaxis-related dermal lesion.

### Claim 45 (depends on 30)

A method of treating, preventing, slowing the progression of, arresting and/or reversing tissue calcification in a pre-diabetic mammal or a mammal with diabetes, chronic kidney disease or a combination thereof, and in need thereof, the method comprising administering to the mammal at least 0.01 mg of the composition of claim 30 per day, to prevent, slow the progression of, and/or arrest tissue calcification, wherein the composition of claim 30 is administered in a pharmaceutical composition.

### Claim 46 (depends on 45)

The method of claim 45, wherein the mammal has chronic kidney disease.

### Claim 47 (depends on 38)

The method of claim 38, wherein the proliferative disease is selected from the group consisting of cancer, leukemia and an inflammatory disease.

### Claim 48 (depends on 30)

A method for treating a mammal with a disease selected from the group consisting of vitamin K deficiency, osteoporosis, a proliferative disease, and a cardiovascular disease, comprising administering to the mammal a therapeutically effective amount of the composition of claim 30.

### Claim 49 (depends on 48)

The method of claim 48, wherein the proliferative disease is selected from the group consisting of melanoma, lung cancer, breast cancer, leukemia, neuroblastoma, glioblastoma, cervical, colorectal, pancreatic, bladder, renal, prostate, ovarian and head and neck.

### Claim 50 (depends on 30)

A method for treating, preventing, slowing the progression of, arresting and/or reversing Alzheimer's disease (AD) in a mammal or a subject in need thereof, the method comprising administering to the mammal or subject at least 0.01 mg of the composition of any one of the composition of claim 30 per day, to prevent, slow the progression of, and/or arrest or reverse Alzheimer's disease.
